Systemic chemotherapy in the management of bladder cancer

1989 ◽  
pp. 143-158 ◽  
Author(s):  
David M. Nanus ◽  
George J. Bosl
Keyword(s):  
Bladder Cancer ◽  
Systemic Chemotherapy

scholarly journals Utility of Inflammation-based Prognostic Scoring in Patients Given Systemic Chemotherapy First-line for Advanced Inoperable Bladder Cancer

2012 ◽  
Vol 42 (10) ◽  
pp. 955-960 ◽  
Author(s):  
E. C. Hwang ◽  
I. S. Hwang ◽  
H. S. Yu ◽  
S.-O. Kim ◽  
S. I. Jung ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Systemic Chemotherapy ◽  
First Line

Treatment of Muscle-Invasive Bladder Cancer in Older Patients

2016 ◽  
pp. e228-e233
Author(s):  
Eila C. Skinner
Keyword(s):  
Bladder Cancer ◽  
Older Patients ◽  
Systemic Chemotherapy ◽  
Population Data ◽  
Invasive Bladder Cancer ◽  
Patient Treatment ◽  
Muscle Invasive Bladder Cancer ◽  
Definitive Therapy ◽  
Localized Disease ◽  
Muscle Invasive

Treatment of muscle-invasive bladder cancer in older patients is challenging. Definitive therapy of localized disease requires either surgery or radiation therapy, ideally combined with systemic chemotherapy. However, current population data suggest that less than half of patients older than age 70 are offered such treatments. We will review tools available to assess the fitness of older patients for surgery, alternatives, and tips for perioperative patient treatment.

Factors associated with perioperative systemic chemotherapy for bladder cancer: A population based study

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4701-4701 ◽  
Author(s):  
J. M. McKiernan ◽  
G. J. Decastro ◽  
S. Gilbert ◽  
V. Grann ◽  
C. A. Olsson ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Systemic Chemotherapy ◽  
Population Based ◽  
Population Based Study ◽  
Factors Associated

Evaluation of systemic chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin for advanced bladder cancer

1992 ◽  
Vol 30 (S1) ◽  
pp. S85-S89 ◽  
Author(s):  
Toshihiko Kotake ◽  
Hideyuki Akaza ◽  
Shigoe Isaka ◽  
Susumu Kagawa ◽  
Kenkichi Koiso ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Systemic Chemotherapy ◽  
Advanced Bladder Cancer

scholarly journals Systemic Chemotherapy for Urothelial Cancer – How to Select Systemic Therapy in Bladder Cancer

2017 ◽  
Vol 13 (02) ◽  
pp. 134 ◽  
Author(s):  
Ioannis Dimitriadis ◽  
Aristotelis Bamias ◽  
◽  
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Chemotherapy ◽  
Disease Management ◽  
Systemic Therapy ◽  
Survival Benefit ◽  
Systemic Chemotherapy ◽  
Urothelial Cancer ◽  
Advanced Disease ◽  
Early Disease ◽  
Chemotherapy Adjuvant

Urothelial cancer (UC) has long been recognised as a chemosensitive disease, and systemic chemotherapy plays a crucial role in the management of localised and advanced disease. Unfortunately, there has been a paucity of progress during the last 15 years in this area. Neoadjuvant use of cisplatin-based combinations has shown survival benefit and together with radical cystectomy should constitute the cornerstone of early disease management. Most importantly, Galsky criteria concerning fitness for cisplatin provide a useful tool for clinicians, in order to select patients with substantial benefit from cisplatin-based chemotherapy. Adjuvant chemotherapy may be useful in selected cases, but its wide implementation has to be proved. Recently, the advent of modern immunotherapy seems to offer new effective choices for patients with advanced UC.

Systemic Therapy for Invasive Bladder Cancer

1996 ◽  
Vol 3 (6) ◽  
pp. 501-506 ◽  
Author(s):  
Milind Javle ◽  
Derek Raghavan
Keyword(s):  
Bladder Cancer ◽  
Survival Benefit ◽  
Systemic Chemotherapy ◽  
Systemic Treatment ◽  
Superficial Bladder Cancer ◽  
Locally Advanced ◽  
Local Therapy ◽  
The United States ◽  
Invasive Disease ◽  
Western Society

Background Bladder cancer is one of the most common malignancies in Western society. In the United States, approximately 10,000 of these patients present with invasive disease, and more progress from superficial bladder cancer. Methods The authors review the literature on systemic treatment for both localized and metastatic bladder cancer, and they include their experience in defining approaches to various stages of disease. Results Cisplatin-based combination chemotherapy is the most effective systemic approach for advanced bladder cancers, although few patients are cured. Neoadjuvant, perspective, and adjuvant trials, as well as concurrent chemoradiation studies, are in progress to attempt to demonstrate better outcomes. Conclusions The combination of systemic chemotherapy and definitive local therapy may have a useful role in the management of locally advanced bladder cancers, but optimal schedules and true survival benefit have not been established.

Sign in / Sign up

Export Citation Format

Share Document